Hints and tips:
Related Special Reports
...The foundation’s philanthropic firepower has surged thanks to sales of diabetes and weight loss drugs by Novo Nordisk, in which the foundation holds a controlling stake through its subsidiary Novo Holdings...
...“What you’ll see us doing . . . is to start to do bigger deals and deploy more equity,” he said....
...But the companies do not have a history of protein manufacturing used by Novo Nordisk and its US rival Eli Lilly to make their diabetes and weight-loss products....
...Holdings, the parent company of Novo Nordisk....
...Novo Holdings, the controlling shareholder in Novo Nordisk, has signed a $16.5bn deal to acquire US-based medicines manufacturer Catalent, in a deal that will bolster the Danish drugmaker’s supply chain....
...The purchase of the three sites was part of a three-way transaction announced on Monday in which Novo Holdings, the Danish group’s controlling shareholder, agreed to buy US drug manufacturer Catalent for...
...The US has become increasingly dominant among global equity markets since the financial crisis as near-zero interest rates lifted the valuations of tech groups with strong profit growth....
...“Once it is complete, which we anticipate around the end of 2024, Novo Nordisk will honour all existing contracts,” the company told the FT on Tuesday. Novo Holdings declined to comment....
...It is the 55-and-over crowd of travellers who have helped fuel the second-largest US initial public offering of 2024, the listing of cruise operator Viking Holdings on Wednesday....
...The same dog-avoidance benefit probably contributed to actives beating passives last year in Denmark, where selling Ørsted and Genmab on the first sniff of trouble while holding on to Novo Nordisk would...
...There was much fanfare in 2023 about Denmark’s Novo Nordisk, which became Europe’s most valuable company....
...The twist is that it is acquiring those sites from Novo Holdings, its own controlling investor, as part of an agreement in which Novo Holdings will first buy US-based Catalent for a $16.5bn total price tag...
...“With buyouts, [we can] hunt for companies in the $5bn range . . . what you’ll see us doing . . . is start to do bigger deals and deploy more equity.”...
...They pointed out, approvingly, that the group managed to track the index while holding a large cash reserve. But holding cash for cash’s sake does not earn companies a gold star....
...Novo Holdings, which manages the foundation’s wealth, has 77 per cent of the voting rights of Novo Nordisk....
...Wood’s stock languishes around 142p — a painful 41 per cent below the final takeover price offered by Apollo a year ago before the private equity group got cold feet....
...The US Food and Drug Administration says there is a shortage of Novo Nordisk’s and Eli Lilly’s diabetes drugs, while Belgium has banned the off-label use of Novo Nordisk’s diabetes drug for obesity treatments...
...European equities were already off to the races, following US stocks higher....
...So, what can the Bloopers tell us about European equities? Obviously, absolutely nothing, but it’s about as good as any other approach....
...Outside of these names, the broader earnings outlook for the equity world is muted.”...
...Keynes was a successful equity investor, managing the endowment of King’s College, Cambridge, from 1921 to 1946....
...In today’s newsletter: Shari Redstone preps Paramount-Skydance merger Exor wins big on litigation in the US Private equity’s boycott challenge in Asia Shari Redstone prepares a new Paramount-Skydance...
...Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk, plans to invest up to $7bn annually by 2030, as dividend payments from the maker of blockbuster diabetes drug Ozempic and weight-loss...
...The sale of DR Horton marked a sudden shift by an investor typically billed as a long-term holder; Berkshire disclosed it had invested in the largest US homebuilder just six months ago....
...BlackRock’s US Equity Factor Rotation ETF (DYNF) is another to be swept up by the model portfolio tide....
International Edition